By Maitane Sardon

Sanofi SA said Monday that the Covid-19 booster vaccine it is developing with U.K. drug company GlaxoSmithKline has shown strong immune response in vaccinated adults in a Phase 3 trial.

The French pharma company said the jointly produced next-generation booster has potential to protect against multiple variants, including Omicron BA.1 and BA.2.

The company also said that another trial has shown that, in adults with two doses of the Pfizer-BioNTech Comirnaty vaccine, the Sanofi-GSK booster generated a higher immune response than the Pfizer-BioNTech's booster.

Write to Maitane Sardon at maitane.sardon@wsj.com

(END) Dow Jones Newswires

June 13, 2022 02:28 ET (06:28 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Giu 2024 a Lug 2024 Clicca qui per i Grafici di Sanofi
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Lug 2023 a Lug 2024 Clicca qui per i Grafici di Sanofi